Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers
- PMID: 25015057
- PMCID: PMC4291310
- DOI: 10.1007/s00520-014-2325-x
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers
Abstract
Purpose: Because as many as 30% of cancer patients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’ perceived knowledge gaps, barriers,and educational interests relevant to CINV.
Methods: An Internet-based survey was developed and was electronically disseminated to members of Medscape, an international Internet-based continuing medical education provider.
Results: A total of 2388 health care providers responded to the survey. Although breakthrough nausea and vomiting was the most common CINV-related issue they managed in the preceding year, managing delayed nausea was the most problematic in that time period. Thirty-two percent of health care providers delayed or discontinued a patient’s chemotherapy because of CINV. Cost of antiemetics, patients’ poor adherence to antiemetic regimens, and health care providers’ underestimation of risk for CINV were all barriers to effective management. Health care providers expressed a wide range of educational interests, including managing breakthrough CINV, keeping up with novel antiemetic agents, and learning about emerging approaches for CINV prevention/management.
Conclusions: This survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancer patients at risk for or suffering from CINV.
Comment in
-
Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need.Support Care Cancer. 2015 Aug;23(8):2211. doi: 10.1007/s00520-015-2711-z. Epub 2015 Mar 28. Support Care Cancer. 2015. PMID: 25821108 No abstract available.
-
Response.Support Care Cancer. 2015 Aug;23(8):2213. doi: 10.1007/s00520-015-2753-2. Epub 2015 May 15. Support Care Cancer. 2015. PMID: 25975674 No abstract available.
Similar articles
-
Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.J Natl Compr Canc Netw. 2012 Feb;10(2):149-57. doi: 10.6004/jnccn.2012.0018. J Natl Compr Canc Netw. 2012. PMID: 22308514
-
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15. Int J Clin Oncol. 2015. PMID: 25681876
-
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.Ann Oncol. 2004 Mar;15(3):526-36. doi: 10.1093/annonc/mdh110. Ann Oncol. 2004. PMID: 14998860
-
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hosp Pract (1995). 2015;43(4):226-34. doi: 10.1080/21548331.2015.1077095. Epub 2015 Aug 26. Hosp Pract (1995). 2015. PMID: 26308912 Review.
-
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Curr Opin Support Palliat Care. 2016 Jun;10(2):180-8. doi: 10.1097/SPC.0000000000000206. Curr Opin Support Palliat Care. 2016. PMID: 27028050 Review.
Cited by
-
Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.Support Care Cancer. 2020 Oct;28(10):4761-4769. doi: 10.1007/s00520-020-05310-6. Epub 2020 Jan 23. Support Care Cancer. 2020. PMID: 31974769 Free PMC article.
-
Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.Medicine (Baltimore). 2016 Jan;95(2):e2476. doi: 10.1097/MD.0000000000002476. Medicine (Baltimore). 2016. PMID: 26765450 Free PMC article.
-
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).Oncol Ther. 2022 Jun;10(1):253-262. doi: 10.1007/s40487-022-00188-2. Epub 2022 Mar 4. Oncol Ther. 2022. PMID: 35246827 Free PMC article.
-
Creation of a Peptide Antagonist of the GFRAL-RET Receptor Complex for the Treatment of GDF15-Induced Malaise.J Med Chem. 2023 Aug 24;66(16):11237-11249. doi: 10.1021/acs.jmedchem.3c00667. Epub 2023 Jul 28. J Med Chem. 2023. PMID: 37506293 Free PMC article.
-
A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.Cancer Chemother Pharmacol. 2017 Sep;80(3):441-449. doi: 10.1007/s00280-017-3387-5. Epub 2017 Aug 5. Cancer Chemother Pharmacol. 2017. PMID: 28780725 Free PMC article. Review.
References
-
- Wintrobe MM, Huguley CM. Nitrogen mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders. Cancer. 1948;1:357–382. - PubMed
-
- Grunberg SM, Slusher B, Rugo HS. Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2013;11(2 Suppl 1):1–18. - PubMed
-
- Grunberg SM, Clark-Snow RA, Koeller J. Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management: proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting. Support Care Cancer. 2010;18(Suppl 1):S1–S10. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical